Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04373148 · ClinicalTrials.gov registry record
Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 316
- Enrollment target
NCT04373148: Completed study, sponsored by Stanford University.
NCT04373148 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 316 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04373148 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 316 participants
- Enrollment target
Study Summary
The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19. Adults and children diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.
Interventions
- OTHER There is no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2020-04-08 |
| Est. Completion | 2022-05-31 |
What the finished NCT04373148 record still lists
NCT04373148 is an observational study that tracks outcomes without assigning an intervention. The registered 316 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which There is no intervention is the first listed.
NCT04373148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04373148 about?
NCT04373148 is a clinical study titled "Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19". The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19. Adults and children diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this s...
What is the current status of trial NCT04373148?
This trial is currently completed. The enrollment target is 316 participants. The study started on 2020-04-08. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04373148?
The interventions under investigation include: There is no intervention (OTHER).
Who is sponsoring clinical trial NCT04373148?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04256317 · 316 participants · Phase 2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- NCT04787042 · 316 participants · Phase 1
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- NCT04802759 · 316 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- NCT05464056 · 316 participants · NA
BUILT Family Lifestyle Program for Children with ADHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI